MannKind | MNKD - Capitale Ordinario





Capitale Ordinario Cambiamento Data
Adma Biologics USD 237.88M 457K 2025-12
BioCryst Pharmaceuticals USD 213.06M 2.54M 2025-12
Eli Lilly USD 946.83M 354.23M 2025-06
Halozyme Therapeutics USD 117.78M 259K 2025-12
Insmed USD 214.26M 1.67M 2025-12
Karyopharm Therapeutics USD 13K 0 2024-09
MacroGenics USD 63.32M 60K 2025-12
MannKind USD 307.83M 806K 2025-12
Merck USD 2.49B 15.79M 2025-09
Minerva Neurosciences USD 1000 0 2024-09
Novavax USD 162.58M 106K 2025-12
Novo Nordisk DKK 4.44B 3.99B 2025-06
Pfizer USD 5.69B 1000K 2025-09
Xencor USD 71.87M 529K 2025-12